Omid Farokhzad
Chief Executive Officer bei SEER, INC.
Vermögen: 10 Mio $ am 31.03.2024
Profil
Gründer von 5 verschiedenen Unternehmen, darunter: Seer, Inc. (Kalifornien), Selecta Biosciences, Inc. und DNIB Unwind, Inc. Omid C. Farokhzad ist ein Unternehmer und ist Chairman & Chief Executive Officer für Seer, Inc. (Kalifornien), das er 2017 gegründet hat. Er ist auch im Vorstand von Placon Therapeutics, Inc. In seiner früheren Laufbahn war er Chairman bei Selecta Biosciences, Inc. (er gründete das Unternehmen im Jahr 2007), außerordentlicher Professor an der Harvard Medical School, Direktor bei DNIB Unwind, Inc. und Direktor bei Tarveda Therapeutics, Inc. Dr. Farokhzad erhielt einen Doktortitel und einen Hochschulabschluss von der Boston University School of Medicine und einen MBA vom Massachusetts Institute of Technology.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
SEER, INC.
87,67% | 31.12.2023 | 3 555 195 ( 87,67% ) | 7 Mio $ | 31.03.2024 |
SEER, INC. CLASS A
2,37% | 07.03.2024 | 1 436 285 ( 2,37% ) | 3 Mio $ | 31.03.2024 |
SENTI BIOSCIENCES, INC.
4,26% | 16.06.2023 | 1 947 403 ( 4,26% ) | 734 171 $ | 31.03.2024 |
Aktive Positionen von Omid Farokhzad
| Unternehmen | Position | Beginn |
|---|---|---|
| SEER, INC. | Chief Executive Officer | 01.03.2018 |
| SENTI BIOSCIENCES, INC. | Director/Board Member | 08.06.2022 |
Placon Therapeutics, Inc.
 Placon Therapeutics, Inc. BiotechnologyHealth Technology Placon Therapeutics, Inc. develops novel platinum therapies. The private company is based in Watertown. | Director/Board Member | - |
| Xlink Therapeutics, Inc. | Founder | - |
PrognomIQ, Inc.
 PrognomIQ, Inc. Medical SpecialtiesHealth Technology PrognomIQ, Inc. operates as a healthcare company, which engages in the development and commercialization of multi-omics human tests for cancer and other complex diseases. It aims to leverage Seer’s Proteograph in addition to genomics and metabolomics technologies, to develop multi-omics products to improve human health. The company is headquartered in Redwood City, CA. | Founder | - |
| Xira Connect, Inc. | Director/Board Member | 01.08.2019 |
Ehemalige bekannte Positionen von Omid Farokhzad
| Unternehmen | Position | Ende |
|---|---|---|
| DYNC SPL | Chairman | 01.06.2022 |
| CARTESIAN THERAPEUTICS, INC. | Founder | 19.11.2019 |
Tarveda Therapeutics, Inc.
 Tarveda Therapeutics, Inc. BiotechnologyHealth Technology Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA. | Founder | 01.01.2019 |
| ░░░░░░░ ░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░ ░░░░░ ░░░░░░░░░░░░ ░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Omid Farokhzad
| MIT Sloan School of Management | Masters Business Admin |
| Boston University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| SEER, INC. | Health Technology |
| SENTI BIOSCIENCES, INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
DNIB Unwind, Inc.
 DNIB Unwind, Inc. BiotechnologyHealth Technology DNIB Unwind, Inc. develops biopharmaceutical preparations. The company was founded by Omid C. Farokhzad and Robert S. Langer on May 19, 2006 and is headquartered in Los Angeles, CA. | Health Technology |
Selecta Biosciences, Inc.
 Selecta Biosciences, Inc. BiotechnologyHealth Technology Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its portfolio includes pipeline, autoimmune, gene therapy, and biologic therapy. The company was founded by Omid C. Farokhzad, Robert S. Langer Jr., and Ulrich von Andrian on December 10, 2007 and is headquartered in Watertown, MA. | Health Technology |
Semaphore, Inc.
 Semaphore, Inc. Packaged SoftwareTechnology Services Part of Roper Technologies, Inc., Semaphore, Inc. develops and distributes advanced financial and project management software. The private company is based in New York, NY. The company was founded by Omid C. Farokhzad. Semaphore was acquired by Deltek Systems, Inc. on August 10, 2000 for $10 million. | Technology Services |
The Brigham & Women's Hospital, Inc.
 The Brigham & Women's Hospital, Inc. Hospital/Nursing ManagementHealth Services The Brigham & Women's Hospital, Inc. provides health care services. The firm offers treatment for cancer, cardio vascular, neurosciences, orthopedic, arthritis, women's health and clinical services. The company was founded in 1980 and is headquartered in Boston, MA. | Health Services |
Tarveda Therapeutics, Inc.
Tarveda Therapeutics, Inc. BiotechnologyHealth Technology Tarveda Therapeutics, Inc. discovers and develops cancer therapeutics and drugs. Its proprietary technology, assets and expertise are built around an integrative research and development process that brings together new-molecule drug discovery engine and patented nanoparticle engineering platform. The company was founded by Omid C. Farokhzad, Stephen J. Lippard and Robert S. Langer Jr., in 2011 and is headquartered in Watertown, MA. | Health Technology |
Placon Therapeutics, Inc.
Placon Therapeutics, Inc. BiotechnologyHealth Technology Placon Therapeutics, Inc. develops novel platinum therapies. The private company is based in Watertown. | Health Technology |
PrognomIQ, Inc.
PrognomIQ, Inc. Medical SpecialtiesHealth Technology PrognomIQ, Inc. operates as a healthcare company, which engages in the development and commercialization of multi-omics human tests for cancer and other complex diseases. It aims to leverage Seer’s Proteograph in addition to genomics and metabolomics technologies, to develop multi-omics products to improve human health. The company is headquartered in Redwood City, CA. | Health Technology |
Dynamics Special Purpose Corp.
 Dynamics Special Purpose Corp. Financial ConglomeratesFinance Dynamics Special Purpose Corp. is a blank check company formed for the purpose of entering into a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination. The company was founded on March 1, 2021 and is headquartered in Redwood City, CA. | Finance |
| Xlink Therapeutics, Inc. | |
| Xira Connect, Inc. |
